By Maria Armental 
 

GlaxoSmithKline PLC's Nucala has been approved in the U.S. as an add-on treatment for children 6 to 11 years old with a severe type of asthma characterized by high levels of white blood cells, the company said Thursday.

Nucala, which contains the active substance mepolizumab, was first approved by the Food and Drug Administration in 2015 as an add-on maintenance treatment for patients with severe eosinophilic asthma at least 12 years old. It has been approved in the European Union for use as an add-on treatment for severe eosinophilic asthma in patients aged 6 and older since August 2018.

 

Write to Maria Armental at maria.armental@wsj.com

 

(END) Dow Jones Newswires

September 12, 2019 16:27 ET (20:27 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Gsk Charts.
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Gsk Charts.